Showing 15 posts of 547 posts found.

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023
Medical Communications CNS, Neurology, Pharmanovia, Sanofi, acquisition

Pharmanovia has announced that it will expand its neurology portfolio with the acquisition of a selection of central nervous system …

Innate Pharma doses first patient in relapsed/refractory multiple myeloma trial

July 11, 2023
Research and Development Innate Pharma, Oncology, Sanofi, clinical trial, multiple myeloma

Innate Pharma has announced that the first patient has been dosed in its Sanofi-sponsored phase 1/2 clinical trial, which aims …


Sanofi shares data about new drug for haemophilia A in paediatric patients

June 26, 2023
Research and Development Haematology, Sanofi, clinical trial, haemophilia a

Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

June 8, 2023
Research and Development Cancer, FDA, Haematology, Innate Pharma, Sanofi, haematology

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US Food and Drug Administration (FDA) …

Sanofi announce positive phase 2 data for MS drug frexalimab

June 1, 2023
Research and Development Neurology, Sanofi, clinical trial, frexalimab, multiple sclerosis

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 clinical study into its relapsing …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

May 3, 2023
Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …

Sanofi complete acquisition of mRNA company Translate Bio

September 15, 2021
Research and Development 2021, 3.2 billion, COVID-19, Sanofi, Translate Bio, acquisition, mrna, vaccines

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal for Translate Bio, a Massachusetts-based …


Sanofi’s NSCLC drug gains EC approval

June 25, 2021
Medical Communications EC, EU, NSCLC, Sanofi

The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the first-line treatment of adults with …


Sanofi’s Libtayo shows positive Phase III results in advanced cervical cancer

May 13, 2021
Libtayo, Sanofi, cemiplimab, cervical cancer

Regeneron Pharmaceuticals and Sanofi have announced today positive Phase III trial results investigating the PD-1 inhibitor Libtayo (cemiplimab) in patients …

Sanofi to collaborate with Stanford University in immunology research

May 6, 2021

Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine, working to advance the understanding of …


Sanofi’s RSV drug sees Phase III clinical trial success

April 26, 2021
Sales and Marketing AstraZeneca, Sanofi

Sanofi have announced positive topline results from the Phase III MELODY trial into nirsevimab, which demonstrated protection against respiratory syncytial …

Sanofi signs €414 million deal for C4XD oral IL-17A inhibitor programme

April 19, 2021
Sales and Marketing Sanofi

Sanofi has signed an exclusive worldwide licensing agreement with C4X Discovery Limited for C4XD’s oral pre-clinical IL-17A inhibitor programme, which …

Sanofi multiple myeloma drug approved for second indication by EC

April 19, 2021
Sales and Marketing European Commission, Sanofi, Sarclisa, pharma, pharma news

The European Commission (EC) has approved a second indication of Sanofi’s Sarclisa drug for the treatment of adult patients with …

Sanofi to invest €400 million on Singapore vaccine production site

April 12, 2021
Sales and Marketing Sanofi, Vaccine

Sanofi have today announced a €400 million investment to create a unique vaccine production centre in Singapore, in partnership with …

New Sanofi Sarclisa treatment for multiple myeloma approved by FDA

April 1, 2021
FDA, FDA Approval, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa drug has been approved by the FDA in combination with carfilzomib and dexamethasone (Kd) for the treatment of …

Latest content